Company Claims Superior Pain Relief, Reduced Paresthesia From New Technology

In a press release last week, St. Jude Medical, Inc., announced the results of a prospective, randomized multicenter study designed to support US approval of its proprietary Burst stimulation technology for treatment of chronic pain. According to the statement, the SUNBURST study demonstrated that Burst stimulation provided superior pain relief in comparison to traditional spinal cord stimulation (SCS). Additionally, the study found that patients voiced a preference for the new technology over SCS, and that they experienced a reduction in, or absence of, paresthesia when receiving Burst stimulation. The study results were presented at the annual meeting of the North American Neuromodulation Society in Las Vegas.

The study enrolled 100 patients from 20 centers across the United States randomized to either receive traditional SCS prior to Burst stimulation, or to receive Burst stimulation prior to traditional SCS. After 6 months, an analysis of the first 85 patients to complete their 24 week visit showed Burst stimulation delivered superior pain relief and reduced paresthesia (a tingling sensation that commonly accompanies traditional SCS) and was preferred by 69.4% of participants for treatment of their pain. According to the company, Burst stimulation differs from traditional SCS in utilizing intermittent “burst” pulses designed to mimic the body’s natural nerve firing patterns and provide a more physiologic therapy method for chronic pain conditions.

The Daily Dose has recently discussed high-frequency spinal cord stimulation, here and here.

Read more about the technology and study results here.

Related Content